About 100 reports

Phase II/ III Clinical Trials Status for HCC ##% ##% ##% ##% ##% ##% Completed Ongoing Terminated Planned Withdrawn Suspended Completed Trials by Drug Molecule Type ##% ##% ##% ##% ##% ##% ##% ##% ##% ##% ##% ##% ##% ##% ##% ##% ##% ##% ##% ##% ##%

  • Hepatitis
  • United States
  • Eli Lilly & Co.
  • MedImmune, LLC
  • Merck & Co., Inc.

The Phase III PHOENIX trial, testing the addition of Imbruvica to the current SOC, R- CHOP, in frontline diffuse large B-cell lymphoma (DLBCL) is expected read out in mid- 2018.

  • Hepatitis
  • United States
  • Merck & Co., Inc.
  • Novartis AG
  • Roche Group
  • CANCER VACCINES MARKET, GLOBAL, INFECTIOUS AGENTS AND ASSOCIATED CANCERS, 2016
  • CANCER VACCINES MARKET, GLOBAL, ANNUAL REVENUE FORECAST FOR HEPATITIS B SURFACE ANTIGEN

The ZUMA-## trial included patients with refractory diffuse large B-cell lymphoma, primary mediastinal Bcell lymphoma and transformed follicular lymphoma.

  • Hepatitis
  • Market Size
  • Juno Therapeutics Inc.
  • Merck & Co., Inc.
  • Novartis AG

No. ## Lize East## Road, Chaoyang District, Beijing, P. R.

  • Hepatitis
  • China
  • Beijing Union Pharmaceutical Co., Ltd.
  • Livzon Group
  • Sichuan Medco Pharmaceutical Stock Co., Ltd.
  • 3.3 IMMUNOGLOBULIN PRODUCTS

Doctors can use the blood to treat patients suffering from a variety of diseases, including lymphoma and anemia. into storage.

  • Hepatitis
  • China
  • East Asia
  • Biotest AG
  • Grifols, S.A.

The auto exports exceeded over ## million each year.

  • Hepatitis
  • China
  • Beijing Union Pharmaceutical Co., Ltd.
  • Livzon Group
  • Sichuan Medco Pharmaceutical Stock Co., Ltd.

COMPANY SNIPPETS.............. ## ##.

  • Hepatitis
  • China
  • United States
  • World
  • Market Shares

On October ##, 2012, the company launched the anaplastic lymphoma kinase (ALK) test in Europe as a companion diagnostic test to aid in identifying individuals who need lung cancer therapy.

  • Hepatitis
  • World
  • Alere Inc.
  • DiaSorin S.p.A.
  • Roche Group

The promising phase ## results led to the initiation of the pivotal phase ## portion of the ZUMA-## study in aggressive non-Hodgkin lymphoma which includes diffuse large B-cell lymphoma, primary mediastinal B-cell lymphoma and transformed follicular

  • Hepatitis
  • HIV AIDS
  • Pharmaceutical
  • United States
  • Gilead Sciences, Inc.

Quantitation of HIV Virus type ## (HIV- ##) on the automated m2000 System.

  • Hepatitis
  • United States
  • Grifols, S.A.
  • Hologic, Inc.
  • Immucor, Inc.
  • Number of Products under Development by Indications, H2 2018
  • Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Primary Outcome Measures include: Efficacy and objective response rate of AT##M when given as a ## hour intravenous infusion twice weekly for two out of three weeks in patients with relapsed mantle cell lymphoma (MCL).

  • Hepatitis
  • Therapy
  • United States
  • Product Initiative
  • Cyclacel Pharmaceuticals, Inc.
  • Number of Products under Development by Indications, H1 2018 (Contd..1), H1 2018
  • Products under Development by Companies, H1 2018

MYC-driven lymphomas are highly sensitive to depletion of Mcl-##.

  • Cancer
  • Hepatitis
  • Pharmaceutical
  • Therapy
  • Cyclacel Pharmaceuticals, Inc.
  • Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98) - Dormant Products

The open-label Phase II study of mocetinostat is expected to enroll ## patients with relapsed and refractory non-Hodgkin' s lymphoma, ## patients with diffuse large B-cell lymphoma and ## with follicular lymphoma.

  • Hepatitis
  • Targeted Therapy
  • United States
  • World
  • Product Initiative
  • MERESTINIB

THE MOLECULES DEVELOPED BY COMPANIES IN PRE-REGISTRATION, PHASE III, PHASE II, PHASE I, PRECLINICAL, DISCOVERY AND UNKNOWN STAGES ARE ##, ##, ##, ##, ##, ## AND ## RESPECTIVELY.

  • Hepatitis
  • Renal Cancer
  • Australia
  • Product Initiative
  • Exelixis, Inc.

The study is a phase I, open-label, multicenter trial of CUDC-## in patients ##-## yrs of age with relapsed/ refractory solid tumors, brain tumors and lymphomas.

  • Hepatitis
  • Therapy
  • United States
  • World
  • Product Initiative

THIS WAS DUE TO ONE LARGE DEAL SETTLED FOR $## BILLION.

  • Hepatitis
  • Infectious Disease
  • Therapy
  • Market Size
  • Gilead Sciences, Inc.
  • NUMBER OF PRODUCTS UNDER DEVELOPMENT BY INDICATION, H1 2018
  • RGT-100 - DRUG PROFILE

Report covers products from therapy areas Infectious Disease and Oncology which include indications Hepatitis B, Viral Infections, Solid Tumor, Human Immunodeficiency Virus (HIV) Infections (AIDS), Liver Cancer, Lymphoma and Multiple Myeloma (Kahler Disease).

  • Hepatitis
  • United States
  • World
  • Product Initiative
  • Rigontec GmbH
  • DELIVERED IN THE PREOPERATIVE WINDOW. THE TRIAL WAS REGISTERED WITH THE U.S NATIONAL INSTITUTES OF HEALTH.

Three patients had a complete response (CR), one with diffuse large B-cell lymphoma (DLBCL) and two with follicular lymphoma (FL).

  • Hepatitis
  • Hospital
  • Lung Cancer
  • United States
  • Merck & Co., Inc.
  • Kaposi sarcoma. The trial is funded by NCI and Merck.
  • The trial was registered with the U.S. National Institutes of Health.

There were ## patients with indolent lymphoma, including chronic lymphocytic leukemia (CLL), follicular lymphoma (FL), marginal zone lymphoma (MZL), and Waldenström' s macroglobulinemia (WM), and ## patients with aggressive lymphoma, including diffuse large B-

  • Hepatitis
  • Monoclonal Antibody
  • North America
  • United States
  • Product Initiative

IT IS IN PHASE II FOR ANAPLASTIC LARGE CELL LYMPHOMA, LEPTOMENINGEAL DISEASE, METASTATIC PANCREATIC CANCER, CHOLANGIOCARCINOMA, PAPILLARY THYROID CANCER, AND METASTATIC MELANOMA.

  • Hepatitis
  • Therapy
  • United States
  • Product Initiative
  • Exelixis, Inc.

ANNOUNCED THE RESULTS OF THE PHASE I CLINICAL TRIAL OF CABOZANTINIB IN PATIENTS WITH ADVANCED SOLID TUMORS OR LYMPHOMA HAVE BEEN PUBLISHED IN THE CURRENT ISSUE OF THE JOURNAL OF CLINICAL ONCOLOGY.

  • Hepatitis
  • Renal Cancer
  • United States
  • Product Initiative
  • Exelixis, Inc.
  • DORMANT PRODUCTS, H2 2018 (CONTD..1), H2 2018

It is in Phase I stage of development for the treatment of relapsed or refractory B-cell non-Hodgkin lymphoma including diffuse large B-Cell lymphoma, follicular lymphoma, mantle cell lymphoma, marginal zone lymphoma, transformed indolent lymphoma and mul

  • Hepatitis
  • Pharmaceutical
  • Therapy
  • United States
  • Product Initiative
  • Research and Development Brief
  • Product Description

IT IS ALSO IN PHASE I/ II STAGE OF DEVELOPMENT FOR THE TREATMENT OF METASTATIC BREAST CANCER (FIRST LINE THERAPY), B-CELL LYMPHOMAS SUCH AS FOLLICULAR LYMPHOMA, DIFFUSE LARGE B-CELL LYMPHOMA, MANTLE CELL LYMPHOMA, SMALL LYMPHOCYTIC LYMPHOMA, BCELL HOD

  • Cancer
  • Hepatitis
  • North America
  • United States
  • Merck & Co., Inc.
  • lenvatinib mesylate
  • PIPELINE BY JOHNSON & JOHNSON, H1 2018

An open label Phase I dose escalation study of E## administered to patients with solid tumors or lymphomas.

  • Hepatitis
  • Renal Cancer
  • United States
  • Product Initiative
  • Eisai Co., Ltd.
  • SPARTALIZUMAB - DRUG PROFILE
  • REGISTERED WITH THE U.S NATIONAL INSTITUTES OF HEALTH.

LYMPHOMA.

  • Hepatitis
  • Therapy
  • North America
  • United States
  • Product Initiative
  • REFRACTORY MULTIPLE MYELOMA. THE TRIAL WAS REGISTERED WITH THE U.S NATIONAL INSTITUTES OF HEALTH.
  • Research and Development Brief

IT IS IN PHASE I STAGE OF DEVELOPMENT FOR NON MUSCLE INVASIVE BLADDER CANCER (FIRST LINE THERAPY), FOLLICULAR LYMPHOMA, MARGINAL ZONE LYMPHOMA, MANTLE CELL LYMPHOMA, CHRONIC LYMPHOCYTIC LEUKEMIA, SMALL LYMPHOCYTIC LYMPHOMA, WALDENSTROM' S MACROGLOBULINEMIA, LY

  • Hepatitis
  • Lung Cancer
  • Therapy
  • United States
  • Product Initiative

It is in Phase I stage of development for non muscle invasive bladder cancer (first line therapy), follicular lymphoma, marginal zone lymphoma, mantle cell lymphoma, chronic lymphocytic leukemia, small lymphocytic lymphoma, Waldenstrom' s macroglobulinemia, ly

  • Hepatitis
  • Lung Cancer
  • United States
  • Product Initiative
  • Merck & Co., Inc.
  • Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98) - Discontinued Products
  • Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98) - Dormant Products

FDA has granted Orphan Drug Designation to mocetinostat for diffuse large B-cell lymphoma (DLBCL).

  • Hepatitis
  • Leukemia
  • United States
  • World
  • Product Initiative
  • SF-1126 - DRUG PROFILE
  • estimated participant enrollment was 20. The trials were registered with the U.S. National Institutes of Health.

NHL Efficacy highlights include: Response Rates observed in patients with NHL: ## percent (## of ##) ORR, including one CR in patients with Marginal Zone Lymphoma (MZL), ## percent (## of ##) ORR, including ## percent CR rate in patients with Mantle Cell Lymphoma (MCL), ## p

  • Hepatitis
  • Lymphoma
  • Pharmaceutical
  • Therapy
  • Merck & Co., Inc.
  • PIPELINE BY JOHNSON & JOHNSON, H2 2018
  • PRODUCTS UNDER DEVELOPMENT BY COMPANIES, H2 2018 (CONTD..4), H2 2018

AN OPEN LABEL PHASE I DOSE ESCALATION STUDY OF E## ADMINISTERED TO PATIENTS WITH SOLID TUMORS OR LYMPHOMAS.

  • Hepatitis
  • Therapy
  • United States
  • Product Initiative
  • Eisai Co., Ltd.